SARS-COV-2 Surrogate Virus Neutralisation Assay

Description

Randox SARS-CoV-2 Surrogate Virus Neutralisation Assay qualitatively detects total neutralising antibodies targeting the viral spike (S) protein receptor-binding domain (RBD) in an isotype- and species-independent manner.

Benefits include:

» Qualitative detection of SARS-CoV-2 virus neutralising antibodies (VNabs).
» Enables identification of a protective immune response to SARS-CoV-2.
» Aids in the stratification of at risk groups where additional booster vaccinations may be required.
» Accurate assessment of herd immunity and measurement of vaccine efficacy.
» Capable of detecting VNabs in an isotype and species independent manner.
» Rapid results (1.5 hours) without the need for Biosafety level 3 requirements.
» Specificity of 100% and sensitivity of 98% compared to conventional virus neutralisation test.
» Direct sample addition to Biochip well. No off-board sample incubation required.

The Randox SARS-CoV-2 Surrogate Virus Neutralisation Assay is available on the Evidence Investigator.

Find out more: www.randox.com/sars-cov-2-surrovate-virus-neutralisation/